CD40LG and COVID-19: The overall prevalence of aPLs, defined as detection of any aPL, including anticardiolipin IgG/IgM, anti-β2-glycoprotein IgG/IgM, or lupus anticoagulant among critically ill patients with COVID-19 within 72 h of ICU admission was 37%, as shown in Table 2.